Sign In
Free Newsletter
Teva wins FDA nod for first generic GLP-1 weight-loss drug
Teva Pharmaceuticals gained FDA approval to launch the first generic GLP-1 drug for weight loss, a liraglutide injection based on Saxenda.
Novo Nordisk halves Ozempic price to $499 for US patients
As part of an effort to improve access to authentic versions of its GLP-1 medications, the drugmaker is cutting the cost of its popular diabetes drug.
Novo Nordisk ends Hims & Hers deal over Wegovy knockoffs
The conclusion of the collaboration comes as the drug maker cites illegal sales of compounded knockoff weight loss drugs and expresses growing concerns over patient safety.
Novo Nordisk expands Wegovy access as FDA bans semaglutide copies
The Swiss drugmaker – which has its U.S. headquarters in Plainsboro – is launching a series of initiatives to offer patients authentic versions of its blockbuster weight-loss treatment.
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
If the administration signs off on the application, the company’s experimental once-daily version will become the first oral GLP-1 for weight loss.
Novo Nordisk scores court win against GLP-1 copycat compounders
A Texas court denied a request to allow continued sales of compounded Wegovy and Ozempic after the FDA ruled the semaglutide shortage has ended.
Drug compounders sue FDA over Novo Nordisk’s Ozempic, Wegovy (updated)
An industry group filed the lawsuit after the health regulator removed semaglutide from its shortage list and told manufacturers they need to stop producing unbranded versions within the next 60 to 90 days.
GLP-1 users spend less at the supermarket, Cornell study finds
As the weight-loss drugs become more popular, consumer habits are starting to reflect changing consumption behavior, including decreasing sales for certain kinds of foods.
EU reportedly reviewing link between Ozempic, rare eye disease
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse drug reaction for the marketed formulations of semaglutide (Ozempic, Rybelsus and Wegovy) as per the approved labels."
Pharma giants defend against high-stakes lawsuit over weight loss drugs
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side effects of their blockbuster diabetes and weight loss medications. NJBIZ recently spoke with legal experts about the status of the litigation, as well as possible effects in areas like public trust and the market for GLP-1 drugs.
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.
Novo Nordisk settles lawsuits over copycat versions of Wegovy, Ozempic
Over the past year, the pharmaceutical company has filed 12 actions against clinics, medical spas and compounding pharmacies across the country that claimed to offer semaglutide, the active ingredient in the medications.
